Your browser doesn't support javascript.
loading
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
Subramanian, Pallavi; Gargani, Sofia; Palladini, Alessandra; Chatzimike, Margarita; Grzybek, Michal; Peitzsch, Mirko; Papanastasiou, Anastasios D; Pyrina, Iryna; Ntafis, Vasileios; Gercken, Bettina; Lesche, Mathias; Petzold, Andreas; Sinha, Anupam; Nati, Marina; Thangapandi, Veera Raghavan; Kourtzelis, Ioannis; Andreadou, Margarita; Witt, Anke; Dahl, Andreas; Burkhardt, Ralph; Haase, Robert; Domingues, António Miguel de Jesus; Henry, Ian; Zamboni, Nicola; Mirtschink, Peter; Chung, Kyoung-Jin; Hampe, Jochen; Coskun, Ünal; Kontoyiannis, Dimitris L; Chavakis, Triantafyllos.
Afiliação
  • Subramanian P; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Gargani S; Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Centre "Alexander Fleming"VariGreece.
  • Palladini A; Paul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital and Faculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Chatzimike M; German Center for Diabetes ResearchNeuherbergGermany.
  • Grzybek M; Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Centre "Alexander Fleming"VariGreece.
  • Peitzsch M; Paul Langerhans Institute Dresden, Helmholtz Zentrum München, University Hospital and Faculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Papanastasiou AD; German Center for Diabetes ResearchNeuherbergGermany.
  • Pyrina I; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Ntafis V; Department of Biomedical SciencesUniversity of West AtticaAthensGreece.
  • Gercken B; Histopathology UnitBiomedical Sciences Research Center "Alexander Fleming"VariGreece.
  • Lesche M; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Petzold A; Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Centre "Alexander Fleming"VariGreece.
  • Sinha A; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Nati M; DRESDEN-concept Genome CenterCenter for Molecular and Cellular BioengineeringTechnische Universität DresdenDresdenGermany.
  • Thangapandi VR; DRESDEN-concept Genome CenterCenter for Molecular and Cellular BioengineeringTechnische Universität DresdenDresdenGermany.
  • Kourtzelis I; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Andreadou M; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Witt A; Department of Internal Medicine IUniversity Hospital and Faculty of Medicine, Technische Universität DresdenDresdenGermany.
  • Dahl A; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Burkhardt R; National Center for Tumor DiseasesPartner Site Dresden, Dresden and German Cancer Research CenterHeidelbergGermany.
  • Haase R; York Biomedical Research Institute, Hull York Medical SchoolUniversity of YorkYorkUK.
  • Domingues AMJ; Institute for Fundamental Biomedical Research (IFBR), Biomedical Sciences Research Centre "Alexander Fleming"VariGreece.
  • Henry I; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
  • Zamboni N; DRESDEN-concept Genome CenterCenter for Molecular and Cellular BioengineeringTechnische Universität DresdenDresdenGermany.
  • Mirtschink P; Institute of Clinical Chemistry and Laboratory MedicineUniversity Hospital RegensburgRegensburgGermany.
  • Chung KJ; Scientific Computing FacilityMax Planck Institute of Molecular Cell Biology and GeneticsDresdenGermany.
  • Hampe J; Scientific Computing FacilityMax Planck Institute of Molecular Cell Biology and GeneticsDresdenGermany.
  • Coskun Ü; Scientific Computing FacilityMax Planck Institute of Molecular Cell Biology and GeneticsDresdenGermany.
  • Kontoyiannis DL; Institute of Molecular Systems BiologyETH ZurichZurichSwitzerland.
  • Chavakis T; Institute for Clinical Chemistry and Laboratory MedicineFaculty of MedicineTechnische Universität DresdenDresdenGermany.
Hepatology ; 75(4): 881-897, 2022 04.
Article em En | MEDLINE | ID: mdl-34519101
ABSTRACT
BACKGROUND AND

AIMS:

NAFLD is initiated by steatosis and can progress through fibrosis and cirrhosis to HCC. The RNA binding protein human antigen R (HuR) controls RNAs at the posttranscriptional level; hepatocyte HuR has been implicated in the regulation of diet-induced hepatic steatosis. The present study aimed to understand the role of hepatocyte HuR in NAFLD development and progression to fibrosis and HCC. APPROACH AND

RESULTS:

Hepatocyte-specific, HuR-deficient mice and control HuR-sufficient mice were fed either a normal diet or an NAFLD-inducing diet. Hepatic lipid accumulation, inflammation, fibrosis, and HCC development were studied by histology, flow cytometry, quantitative PCR, and RNA sequencing. The liver lipidome was characterized by lipidomics analysis, and the HuR-RNA interactions in the liver were mapped by RNA immunoprecipitation sequencing. Hepatocyte-specific, HuR-deficient mice displayed spontaneous hepatic steatosis and fibrosis predisposition compared to control HuR-sufficient mice. On an NAFLD-inducing diet, hepatocyte-specific HuR deficiency resulted in exacerbated inflammation, fibrosis, and HCC-like tumor development. A multi-omic approach, including lipidomics, transcriptomics, and RNA immunoprecipitation sequencing revealed that HuR orchestrates a protective network of hepatic-metabolic and lipid homeostasis-maintaining pathways. Consistently, HuR-deficient livers accumulated, already at steady state, a triglyceride signature resembling that of NAFLD livers. Moreover, up-regulation of secreted phosphoprotein 1 expression mediated, at least partially, fibrosis development in hepatocyte-specific HuR deficiency on an NAFLD-inducing diet, as shown by experiments using antibody blockade of osteopontin.

CONCLUSIONS:

HuR is a gatekeeper of liver homeostasis, preventing NAFLD-related fibrosis and HCC, suggesting that the HuR-dependent network could be exploited therapeutically.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / Proteína Semelhante a ELAV 1 / Neoplasias Hepáticas Limite: Animals Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / Proteína Semelhante a ELAV 1 / Neoplasias Hepáticas Limite: Animals Idioma: En Revista: Hepatology Ano de publicação: 2022 Tipo de documento: Article